Pfizer gives additional $530,000 for UICC breast cancer research

Pfizer Inc. is renewing its partnership with the Union for International Cancer Control (UICC) through a grant of $530,000 for the Seeding Progress and Resources for the Cancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge.
“To date, the impact of the SPARC MBC Challenge has been significant and far-reaching, helping metastatic breast cancer patients around the world with diverse backgrounds, needs and aspirations,” Pfizer Oncology President and General Manager Liz Barrett said. "We are committed to expanding this bold initiative with UICC with the aim of further improving the outlook for these patients and fostering an environment where they feel validated and supported.”
The challenge has provided grants to organizations around the world to help address the challenges, which are not constrained to treatment, faced by women with metastatic breast cancer around the world. Pfizer launched the challenge with UICC in 2015 with $760,000 in funding.
“UICC and its members are delighted to continue working with our partner Pfizer on this first-of-its-kind program,” UICC CEO Cary Adams said. “We look forward to…asking groups worldwide to propose projects that will close the gaps between metastatic breast cancer and early breast cancer awareness and support.”